Patent US4863949A successfully refreshed from Google Patents.
US4863949A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Aminopropanol derivatives, processes for the preparation thereof, the use thereof and pharmaceutical compositions containing them
Assignee: Roche Diagnostics GmbH
•
Filing: 1987-09-21
•
Granted: 1989-09-05
•
Expires: 2007-09-21
Abstract
Abstract The present invention provides compounds of the general formula: <IMAGE> (I) wherein Ar is a substituted or unsubstituted aromatic or heteroaromatic radical, A is a straight-chained or branched alkylene chain containing up to 8 carbon atoms, a -CH2- group of which can be replaced by a cycloalkylene radical containing 3 to 7 carbon atoms, B is a straight-chained mono- or bicyclic, optionally branched, saturated or unsaturated alkylene chain containing up to 12 carbon atoms, a -CH2- group of which can be replaced by a cycloalkylene radical containing 3 to 7 carbon atoms and/or up to two -CH2- groups of which can be replaced by an oxygen or a sulphur atom or by an -S(=O) or -S(=O)2 group, X is a valency bond, an oxygen atom or an -NR1 group, in which R1 is a hydrogen atom or a straight-chained or branched, saturated or unsaturated alkyl or nitroxyalkyl radical containing up to 6 carbon atoms or R1, together with the nitrogen atom of the -NR1- group and a -CH2- group of the chain B, can form a heteroaliphatic ring containing 4 to 6 carbon atoms and n is 1, 2 or 3; and the physiologically acceptable salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them. Furthermore, the present invention is concerned with the use of these compounds for the treatment and/or prophylaxis of heart and circulatory diseases.
Inventors
- 👤 Herbert Simon
- 👤 Helmut Michel
- 👤 Wolfgang Bartsch
- 👤 Klaus Strein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 10:29
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/04; C07D209/08; A; A61; A61P; A61P25/00; A61P25/02; A61P9/00; A61P9/08; A61P9/10; C07C; C07C255/00; C07D209/30; C07D209/32; C07D209/34; C07D209/42; C07D215/00; C07D215/02; C07D215/16; C07D215/20; C07D215/22; C07D215/227; C07D311/00; C07D311/02; C07D311/04; C07D311/06; C07D311/08; C07D311/18
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
241 words
A compound of the formula ##STR14## wherein Ar is an indole or indoline which are unsubstituted or substituted one or more times by C 1 -C 3 hydroxyalkyl, formyl, C 1 -C 3 alkanoyl, C 1 -C 3 alkylcarbonylamino, cyano, oxo, hydroxyl, carbamoyl or C 1 -C 3 alkyl, A is a straight-chained or branched C 1 -C 8 alkylene chain, a --CH 2 -- group which can be replaced by a C 3 -C 7 cycloalkylene, B is a straight-chained, mono- or bicyclic, optionally branched, saturated or unsaturated C 1 -C 12 alkylene chain, a --CH 2 -- group which can be replaced by a C 3 -C 7 cycloalkylene or up to two --CH 2 -- groups of which each can be replaced by an oxygen or a sulphur atom or by an --S(═O) or --S(═O) 2 group, X is a valency bond, an oxygen atom or an --NR 1 -- group, in which R 1 is a hydrogen atom or a straight-chained or branched, saturated or unsaturated C 1 -C.sub. 6 alkyl or nitroxyalkyl radical or R 1 , together with the nitrogen atom of the --NR 1 -group and a --CH 2 -- group of the chain B, can form a C 4 -C 6 heterocyclic ring and n is 1, 2 or 3 or a physiologically acceptable salt thereof with the proviso that when n is 2 or 3 the nitroxy group cannot be geminally substituted.
Claim 2
Dependent Claim
241 words
A compound of the formula ##STR14## wherein Ar is an indole or indoline which are unsubstituted or substituted one or more times by C 1 -C 3 hydroxyalkyl, formyl, C 1 -C 3 alkanoyl, C 1 -C 3 alkylcarbonylamino, cyano, oxo, hydroxyl, carbamoyl or C 1 -C 3 alkyl, A is a straight-chained or branched C 1 -C 8 alkylene chain, a --CH 2 -- group which can be replaced by a C 3 -C 7 cycloalkylene, B is a straight-chained, mono- or bicyclic, optionally branched, saturated or unsaturated C 1 -C 12 alkylene chain, a --CH 2 -- group which can be replaced by a C 3 -C 7 cycloalkylene or up to two --CH 2 -- groups of which each can be replaced by an oxygen or a sulphur atom or by an --S(═O) or --S(═O) 2 group, X is a valency bond, an oxygen atom or an --NR 1 -- group, in which R 1 is a hydrogen atom or a straight-chained or branched, saturated or unsaturated C 1 -C.sub. 6 alkyl or nitroxyalkyl radical or R 1 , together with the nitrogen atom of the --NR 1 -group and a --CH 2 -- group of the chain B, can form a C 4 -C 6 heterocyclic ring and n is 1, 2 or 3 or a physiologically acceptable salt thereof with the proviso that when n is 2 or 3 the nitroxy group cannot be geminally substituted.
Claim 3
Dependent Claim
150 words
The compound of claim 1, wherein Ar is an indole or indoline which are unsubstituted or substituted one or more times by hydroxyalkyl, formyl, alkanoyl, alkylcarbonylamino, cyano, oxo, hydroxyl, carbamoyl or alkyl, A is a straight-chained or branched C 1 -C 8 alkylene chain, B is a straight-chained or bicyclic, optionally branched, saturated C 1 -C 12 alkylene chain, a --CH 2 -- group which can be replaced by a C 3 -C 7 cycloalkylene or up to two --CH 2 -- groups which each can be replaced by an oxygen or a sulphur atom or by an --S(═O) or --S(═O) 2 group, X is a valency bond, an oxygen atom or an --NR 1 -- group, wherein R 1 is a hydrogen atom, a straight-chained or branched, saturated or unsaturated C 1 -C 6 alkyl or nitroxyalkyl and n is 1 or 2; or a physiologically acceptable salt thereof.
Claim 4
Dependent Claim
88 words
The compound of claim 2 wherein Ar is an indole or indoline selected from the group consisting of 2-methyl-4-indolyl, 3-methyl-4-indoly, 6-methyl-4-indolyl, 2-ethyl-4-indolyl, 6-ethyl-4-indolyl, 2,3-dimethyl-4-indolyl, 2,6-dimethyl-4-indolyl, 2-methyl-3-ethyl-4-indolyl, 2-ethyl-3-methyl-4-indolyl, 2,3-diethyl-4-indolyl, 2-cyano-4-indolyl, 3-cyano-4-indolyl, 2-cyano-6-methyl-4-indolyl, 3-cyano-4-indolyl, 2-cyano-6-methyl-4-indolyl, 3-cyano-6-methyl-4-indolyl, 2-carbamoyl-4-indolyl, 3-carbamoyl-4-indolyl, 6-carbamoyl-4-indolyl, 2-carbamoyl-6-methyl-4-indolyl, 2-hydroxymethyl-4-indolyl, 2-hydroxymethyl-5-indolyl, 3-hydroxymethyl-4-indolyl, 2-(2-hydroxyethyl)-4-indolyl, 2-oxoindolin-4-yl, 2-oxoindolin-5-yl, 3-methyl-2-oxo-indolin-4-yl, 3-ethyl-2-oxoindolin-4-yl, 3-isopropyl-2-oxoindolin-4-yl, 3,3-dimethyl-2-oxoindolin-4-yl and 3,3-diethyl-2-oxoindolin-4-yl; A is a straight-chained or branched C 1 -C 8 alkylene chain, B is a straight-chained or branched C 1 -C 12 alkylene, X is a valency bond and n is 1, or a physiologically acceptable salt thereof.
Claim 5
Dependent Claim
12 words
A physiologically acceptable salt of the compound of claim 1 designated 1-(indol-4-yloxy)-3-[2-(4-nitroxybutanoylamino)ethylamino]-propan-2-ol.
Claim 6
Dependent Claim
12 words
A physiologically acceptable salt of the compound of claim 1 designated 3-[2-(4-nitroxybutanoylamino)-ethylamino]-1-(2-oxoindolin-4-yloxy)-propan-2-ol.
Claim 7
Dependent Claim
12 words
A physiologically acceptable salt of the compound of claim 1 designated 3-[2-(4-nitroxypentanoylamino)-ethylamino]-1-(2-oxoindolin-4-yloxy)-propan-2-ol.
Claim 8
Dependent Claim
12 words
A physiologically acceptable salt of the compound of claim 1 designated 3-[2-(5-nitroxypentanoylamino)-ethylamino]-1-(2-oxoindolin-4-yloxy)-propan-2-ol.
Claim 9
Dependent Claim
28 words
A pharmaceutical composition containing an effective amount of the compound of claim 1 for the treatment or prophylaxis of heart and circulatory diseases, in a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
15 words
The pharmaceutical composition of claim 8 wherein said compound is 3-[2-(4-nitroxybutanoylamino)-ethylamino]-1-(2-oxo-indolin-4-yloxy)-propan-2-ol, 3-[2-(5-nitroxypentanoylamino)-ethylamino]-1-(2-oxoindolin-4-yloxy)-propan-2-ol, 3-[2-(4-nitroxypentanoylamino)-ethylamino]-1-(2-oxoindolin-4-yloxy)-propan-2-ol or 1-(indol-4-yloxy)-3-[2-(4-nitroxybutanoylamino)-ethylamino]-propan-2-ol.
Claim 11
Dependent Claim
14 words
The pharmaceutical composition of claim 8 containing 10 to 500 mg of said compound.
Claim 12
Dependent Claim
14 words
The pharmaceutical composition of claim 10 containing 10 to 200 mg of said compound.
Claim 13
Dependent Claim
23 words
A method for treatment of or prophylaxis of heart and circulatory diseases comprising administering an effective amount of the compound of claim 1.
Claim 14
Dependent Claim
15 words
The method of claim 12 wherein 5 to 500 mg of the compound are administered.
Claim 15
Dependent Claim
23 words
A method for treatment of or prophylaxis of heart and circulatory diseases comprising administering an effective amount of the composition of claim 9.
Claim 16
Dependent Claim
28 words
A method for simultaneously producing nitrate-like and beta-blocking effect for the treatment of heart and circulatory diseases comprising administering an effective amount of the compound of claim 1.
References Cited (Backward Citations)
US3644469A
Cited
NL7208332A
Cited
US3928412A
Cited
US3911136A
Cited
US4086357A
Cited
US4419363A
Cited
US4288452A
Cited
CH636856A5
Cited
GB2044251A
Cited
JPS5677257A
Cited
DE3426419A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-09-04 | 1993-03-06 | 1993-09-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-09-04 | 1997-03-06 | 1997-09-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-09-04 | 2001-03-06 | 2001-09-05 | $7700.00 | Window Closed / Lapsed |